$0.72 EPS Expected for Omnicell, Inc. (NASDAQ:OMCL) This Quarter

Equities analysts predict that Omnicell, Inc. (NASDAQ:OMCL) will announce earnings per share (EPS) of $0.72 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Omnicell’s earnings, with the highest EPS estimate coming in at $0.73 and the lowest estimate coming in at $0.70. Omnicell posted earnings of $0.63 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 14.3%. The company is expected to report its next earnings report on Thursday, October 24th.

According to Zacks, analysts expect that Omnicell will report full-year earnings of $2.79 per share for the current financial year, with EPS estimates ranging from $2.75 to $2.81. For the next fiscal year, analysts forecast that the firm will report earnings of $3.02 per share, with EPS estimates ranging from $2.88 to $3.12. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Omnicell.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 25th. The company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.04. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $214.13 million. Omnicell had a return on equity of 11.85% and a net margin of 5.70%. Omnicell’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.

OMCL has been the subject of a number of recent research reports. Zacks Investment Research upgraded Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, July 29th. ValuEngine downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 12th. BidaskClub cut Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. Benchmark lifted their price target on Omnicell from $82.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Craig Hallum raised Omnicell from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a research note on Friday, July 26th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $79.11.

In other Omnicell news, EVP Nhat H. Ngo sold 4,948 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $87.08, for a total value of $430,871.84. Following the completion of the sale, the executive vice president now owns 30,321 shares in the company, valued at $2,640,352.68. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Scott Peter Seidelmann sold 8,500 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $81.68, for a total value of $694,280.00. Following the sale, the executive vice president now owns 28,929 shares of the company’s stock, valued at approximately $2,362,920.72. The disclosure for this sale can be found here. Insiders sold a total of 40,375 shares of company stock worth $3,291,918 over the last ninety days. Insiders own 2.77% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Whittier Trust Co. bought a new stake in shares of Omnicell in the 2nd quarter valued at approximately $26,000. Parallel Advisors LLC bought a new stake in shares of Omnicell during the 1st quarter worth approximately $28,000. Nisa Investment Advisors LLC lifted its stake in shares of Omnicell by 125.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock worth $44,000 after acquiring an additional 300 shares during the last quarter. Manchester Capital Management LLC bought a new stake in shares of Omnicell during the 1st quarter worth approximately $49,000. Finally, Financial Gravity Wealth Inc. purchased a new position in Omnicell during the 1st quarter worth $50,000. Institutional investors and hedge funds own 97.37% of the company’s stock.

NASDAQ:OMCL traded down $0.53 during mid-day trading on Friday, reaching $69.09. The stock had a trading volume of 6,509 shares, compared to its average volume of 683,229. The company has a 50 day moving average price of $78.69. The company has a market capitalization of $2.94 billion, a PE ratio of 44.95, a P/E/G ratio of 2.32 and a beta of 1.11. Omnicell has a one year low of $56.96 and a one year high of $92.59. The company has a quick ratio of 1.54, a current ratio of 2.03 and a debt-to-equity ratio of 0.10.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Further Reading: How does a margin account work?

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.